AFFILIATIONS
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
4 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
5 Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
6 Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
7 Texas A&M University, Houston, Texas, United States
8 Texas A&M University, Houston, Texas, United States
9 Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States
10 Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States, Harvard University, Boston, Massachusetts, United States
11 Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States, Harvard University, Boston, Massachusetts, United States
12 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
13 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
14 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
15 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
16 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
17 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
18 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
19 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
ABSTRACT
Background: Fanconi Anemia (FA) is an inherited DNA repair disorder, and to a variable degree, a syndrome of accelerated aging with increased cancer susceptibility (Mejia-Marrera et al., Front Aging, 2026; Nalepa and Clapp, Nat Rev Cancer, 2018) and increased oxidative stress leading to chronic inflammation (Repcyznska et al., Int J Mol Sci, 2024; Du et al., Antioxid Redox Signal, 2008). In-vitro studies have shown that an intact FA pathway is critical for telomere maintenance (Sarkar and Liu, DNA Repair (Amst.), 2016) and suppression of Long Interspersed Nuclear Element-1 (LINE-1) retrotransposition (Bona and Crossan, Nat Struct Mol Biol, 2023), both of which are mechanisms that share reverse transcriptase activity and are known to overlap (Aschacher et al, Oncogene, 2015), but have not been studied in human subjects. We hypothesized that dysregulated LINE-1 expression and abnormal telomere maintenance contribute to the aging phenotype and associated cancer risk in FA that may serve as targets for intervention.
Methods: We studied 285 longitudinal plasma and marrow samples from 47 individuals with FA (median age 7.0 years (range 0.7 to 32.1 years), including 8 unique FA genotypes) that were collected serially over 20 years. Samples were evaluated for key biomarkers of accelerated aging including: (1) telomere maintenance by high-resolution, single telomere length analysis (STELA) in paired samples separated by a median of 8.0 years from 34 non-transplanted individuals with FA; (2) longitudinal plasma-derived exosomal LINE-1 ORF1 mRNA and protein quantification in 10 non-transplanted individuals with FA; and (3) clonal hematopoiesis of indeterminate potential (CHiP) in 20 non-transplanted young adults with FA (ages 18-30 years).
Results: Telomere maintenance was abnormal in 29 of 34 (85%) patients, with sample pairs separated by a median of 8.0 years (range 3.6-20.1 years). Two distinct phenotypes were observed. Seven of 34 (21%) patients saw no decline in telomere length or gained as many as 205 bp/year over the period of observation. In contrast, twenty-two patients (65%) exhibited accelerated telomere attrition with losses of up to 225 bp/year in comparison to age-based normative losses of around 20-30 bp/year after age 2.
Quantification of exosomal LINE-1 mRNA levels in yearly plasma samples in a subset of patients were found to be up to 34-fold higher in individuals with FA compared to age and sex-matched healthy controls (p <0.0001). LINE-1 protein expression was confirmed via ultra-sensitive digital immunoassay. Of note, LINE-1 mRNA and protein were detectable decades prior to onset of severe marrow failure requiring hematopoietic stem cell transplant (HSCT) and/or development of malignancy, suggesting that peripheral LINE-1 may serve as an immunogenic trigger leading to telomere attrition and stem cell exhaustion.
We next investigated potential mechanisms of telomere preservation and elongation, including telomerase reactivation via a telomeric repeat amplification protocol (TRAP) assay and alternative lengthening of telomeres (ALT) via quantification of telomeric C-circles. Preliminary functional TRAP studies support the possibility of telomerase reactivation in some, though not all, individuals with FA. ALT was absent in all 34 individuals with FA analyzed.
Lastly, CHiP analysis identified clonal hematopoiesis in 2 of 20 (10%) patients (ages 24 and 26 years) driven by TET2 (VAF 8.5%) and SETBP1 (VAF 10%) mutations at a time when both patients had no malignancy. Loss of function mutations in these genes may facilitate LINE-1 reactivation, as many of the epigenetic mutations that define clonal hematopoiesis (i.e. TET2) have established roles in the regulation of LINE-1 silencing (de la Rica et al., Genome Biol, 2016).
Conclusions: These findings support premature aging as an important feature of the FA phenotype. Abnormal telomere dynamics, increased LINE-1 reactivation, and early-onset CHiP identify hallmarks of aging that may contribute to marrow failure, malignancy risk, and premature death in this uniquely at-risk population. Future work will explore the mechanistic relationship between telomere maintenance, LINE-1 activity and retrotransposition, and the collective contribution to chronic inflammation and accelerated aging in FA. Early intervention to modify these pathways may be a route to long-term improvement of the FA phenotype.
This work was sponsored by a 2025 ASH RTAF awarded to Dr. K.N. Ramos.